Seelos Therapeutics' Aggressive Alzheimer's Hopeful Candidate Shows Encouraging Preclinical Activity
Portfolio Pulse from Vandana Singh
Seelos Therapeutics Inc (NASDAQ:SEEL) announced encouraging preclinical data from an in vivo study of SLS-005 in an aggressive Alzheimer's disease non-human primate model. The study showed a 46% reduction in tau protein and an 18% reduction in NfL, a protein biomarker. Top-line data from the SLS-005 registrational Phase 2/3 trial in ALS is expected to be released in Q4 of 2023. However, Seelos' Phase 2 study of SLS-002 for Acute Suicidal Ideation and Behavior failed to meet the pre-defined primary endpoint. SEEL shares are up 13.50% at $0.20.
September 27, 2023 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seelos Therapeutics' SLS-005 shows promising preclinical results in Alzheimer's study, which could potentially boost the company's stock. However, the failure of SLS-002 in Phase 2 study could have a negative impact.
The promising preclinical results of SLS-005 could potentially attract investors, leading to a rise in the company's stock. However, the failure of SLS-002 in Phase 2 study could dampen investor sentiment, potentially leading to a drop in the stock price. The net effect is likely to be positive in the short term, as reflected in the 13.50% rise in SEEL shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100